
The chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
The chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
The chief medical officer of Celularity discussed MLASC and a new analysis of gene and protein signatures from patients treated in legacy clinical trials that he presented at ASGCT’s 2023 conference.
Published: August 16th 2024 | Updated: August 19th 2024
Published: March 18th 2024 | Updated: June 3rd 2024
Published: December 7th 2024 | Updated:
Published: December 12th 2022 | Updated:
Published: July 14th 2024 | Updated:
Published: May 18th 2023 | Updated: